Products for Research Use Only
RegisterLogin

Deracoxib-d3

CAT: 0804-HY-17509S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17509S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Deracoxib-d3 (SC 046-d3; SC 59046-d3) is the deuterium labeled Deracoxib. Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
CAS Number
2012598-48-8
Product Name Alternative
SC 046-d3; SC 46-d3; SC 59046-d3
UNSPSC
12352005
Target
Apoptosis; COX; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Immunology/Inflammation; Others
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Solubility
10 mM in DMSO
Smiles
O=S(C1=CC=C(N2N=C(C(F)F)C=C2C3=CC=C(OC([2H])([2H])[2H])C(F)=C3)C=C1)(N)=O
Molecular Formula
C17H11D3F3N3O3S
Molecular Weight
400.39
References & Citations
[1]Bienhoff, S.E., et al., Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg, 2012. 41 (3) : p. 336-44.|[2]McMillan, S.K., et al., Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc, 2011. 239 (8) : p. 1084-9.|[3]Royals, S.R., et al., Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res, 2005. 66 (11) : p. 1961-7.|[4]Ustun Alkan, F., et al., The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal, 2012. 2012: p. 976740.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-17509-01Deracoxib
HY-W703540Deracoxib-d4
HY-17509R-01Deracoxib (Standard)
HY-15398S3-01Vitamin D3-d3
HY-132348S1Granisetron-d3 (1-methyl-d3)
HY-150954SL-Methionine-d3 (S-methyl-d3) Methyl-d3-sulfonium Chloride
HY-W758392(±) -Ipratropium-d3 Bromide (N-methyl-d3)
HY-B1213AS-01Trimipramine-d3 (N-methyl-d3) (maleate)
HY-104074SPocapavir-d3
HY-W768883β-Nicotyrine-d3

Alternative Products

CatalogName
CS-W-00165Deracoxib-d3
FD21070-01Deracoxib
AR-D06784-01Deracoxib-d4
A18077-50Deracoxib 50mg

Popular Products